Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8929852 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL25640234 | 1.00 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27275066 | 0.87 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL21246536 | 0.86 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL18820117 | 0.83 | ALDH1A1 (0.51) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL27293680 | 0.83 | POLB (0.51) | ALDH1A1KMT2A | |
| SCHEMBL23139036 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL29115740 | 0.83 | ALDH1A1 (0.55) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL29006983 | 0.83 | TSHR (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 | |
| SCHEMBL265176 | 0.82 | ALDH1A1 (0.58) | ALDH1A1TDP1MAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161279-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | AMGEN INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180078532-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | AMGEN INC. (US) | 2018-03-22 | — | — | US | disclosed |
| US-9403868-B2 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160213610-A1 | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | ONYX THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9295708-B2 | Modified release formulations for oprozomib | ONYX THERAPEUTICS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9205126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205124-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150175656-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-9051353-B2 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-8822512-B2 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140113855-A1 | Modified Release Formulations for Oprozomib | ONYX THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-20140050737-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140031297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140024804-A1 | Crystalline Tripeptide Epoxy Ketone Protease Inhibitors | ONYX THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120088903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ALDH1A1 3041/4885TDP1 1396/4885MAPK1 2644/4885 |
| US-20180078532-A1 | IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB | OPRL1, OPRK1, OPRM1 | ALDH1A1 2790/4885TDP1 3397/4885MAPK1 3300/4885 |
| US-20160213610-A1 | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | OPRL1, OPRM1, OPRK1 | ALDH1A1 3123/4885TDP1 2628/4885MAPK1 3900/4885 |
| US-20140113855-A1 | Modified Release Formulations for Oprozomib | OPRL1, OPRM1, OPRK1 | ALDH1A1 3123/4885TDP1 2628/4885MAPK1 3900/4885 |
| US-20180161279-A1 | GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF | GIPR, OPRL1, MLNR | ALDH1A1 3729/4885TDP1 4689/4885MAPK1 3223/4885 |
| US-20140050737-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ALDH1A1 3041/4885TDP1 1396/4885MAPK1 2644/4885 |
| US-20140031297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ALDH1A1 3041/4885TDP1 1396/4885MAPK1 2644/4885 |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | ALDH1A1 3164/4885TDP1 1721/4885MAPK1 3268/4885 |
| US-20140024804-A1 | Crystalline Tripeptide Epoxy Ketone Protease Inhibitors | PREP, CTSC, PEPD | ALDH1A1 2956/4885TDP1 1575/4885MAPK1 3821/4885 |
| US-20150175656-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | ALDH1A1 2956/4885TDP1 1575/4885MAPK1 3821/4885 |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | CTSC, PEPD, PREP | ALDH1A1 3205/4885TDP1 885/4885MAPK1 4042/4885 |
| US-20120088903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | ALDH1A1 2956/4885TDP1 1575/4885MAPK1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.